Donafenib (Sorafenib D3; Bay 43-9006 D3; CM-4307; Zepsun), the tri-deuterated (terminal CD3) form of Sorafenib, is a novel, potent and orally bioavailable multikinase inhibitor that has been approved in China (in 2021) for clinical uses to treat patients with unresectable hapatic tumors. It inhibits Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib was under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC). Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

纯度：≥98%

CAS：1130115-44-4